Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Thymosin α1 plus immune checkpoint inhibitors in malignant tumors
ChiCTR2100043329Phase 4Recruiting
- Sponsor
- Beidahuang Group General Hospital
- Start
- Feb 2021
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thymosin alpha 1 in Non-hematologic malignancy and hematopoietic malignancies, sponsored by Beidahuang Group General Hospital. Primary endpoints: Overall survival, Progression-free survival and 8 more. Started Feb 2021; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2100043329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043329.